SKIN Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -15.58%, SMA50 -28.02%, SMA200 -40.93%). The stock’s 14-day RSI is 29.98 (weak momentum), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -63.87% below its high and over 24.62% above its low. Average 10-day trading volume of 628.69 thousand shares is in line with the 3-month average of 681.04 thousand, indicating normal recent market interest.

The Beauty Health Company generated EPS of -$0.22 over the past year. Five-year average earnings growth is -48.09%. Wall Street analysts project EPS growth of 8.28% annually over the next five years. The latest quarter delivered EPS of -$0.09. The next quarter is forecast at -$0.05. Next year's EPS is expected at $256.32. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 5 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $3.50 to $1.50. The high target offers 297.73% upside. The low target suggests 70.45% downside. The mean target is $2.04. This offers 131.82% upside. The Beauty Health Company earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 12.5%. The prior quarter beat by -150.0%. Over the last six quarters, Apple has recorded several small beats. These include 100.0% in August 08, 2024.

The Beauty Health Company has 126.83 million shares outstanding. The public float is 81.55 million shares, elevated short interest at 27.00% of float. This equals 15.47 million shares. The short ratio is 11.39 days. Institutional investors hold 106.65% of the float. Insiders own 15.29%. SAUNDERS BRENT L holds 5.92 million shares, Stanleick Andrew Roy has 702.93 thousand shares and MONAHAN MICHAEL P. has 358.11 thousand shares.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

The Beauty Health Company (NASDAQ:SKIN) closed at $0.88 USD, losing -$0.03 (-3.22%) from the previous close of $0.91. The stock is currently mid-range between its 52-week high and low $0.76 and $2.69. With a market capitalization of about $112.86 million, The Beauty Health Company is classified as a micro-cap and shows market-like volatility (beta ~1.24). Key stats such as the average daily volume over the past year has been around 691.45 thousand shares, volume is running light vs its 52-week average. Headquartered in Long Beach, CA, The Beauty Health Company operates in the Consumer Defensive sector and the Household & Personal Products industry. Led by CEO Pedro Malha, the company employs approximately 769 people and listed since November 24, 2020. The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide.

The Beauty Health Company trades at a P/E ratio of -11.91, slightly below the S&P 500 average, with a price-to-sales ratio of 0.38 and a price-to-book ratio of 1.85 suggesting the stock is closer to book value. The P/FCF stands at 3.13, also below market averages.

Our AI price prediction model suggests that The Beauty Health Company stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.9%, with price expected at $0.84 by May 04, 2026, within a range of $0.70 to $0.97 3-Month Outlook: Projected rise of 44.91%, reaching $1.28 by July 16, 2026, with a range of $1.19 to $1.36. 1-Year Outlook: Projected loss of -38.87%, with price at $0.54 by April 20, 2027, within a range of $0.00 to $0.00.

The Beauty Health Company (NASDAQ:SKIN) shares are flat 3.6% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows The Beauty Health Company trading at a premium to the broader market with a P/E of -11.91. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $15.67, suggesting 1674.03% upside. Our AI forecast model points to short-term weakness (-4.9% over two weeks), a medium-term rise (44.91% over three months), and a longer-term loss (-38.87% over one year), with expected trading ranges indicating moderate volatility.